Many times when bad news happens in biopharma, investors can't say they weren't warned, as is the case with Solid Biosciences Inc., which provided investors a more than 70% return in the month and a half following its initial public offering. However, those gains have now turned into a significant loss.
Cambridge, Mass.-based Solid launched one of the largest IPOs this quarter on Jan. 25, even after disclosing that the clinical trial for its lead Duchenne muscular dystrophy (DMD) candidate was on a partial clinical hold. Also see "IPO Update: Seven In January As Big Returns, Solid's Slip-Up Contribute To Bubble Concerns" - Scrip, 2 February, 2018. The company gave its IPO investors a 70.1% return as of Feb. 1, which rose to 76.2% by March 9
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?